[go: up one dir, main page]

FI933810L - Reseptorantagonister av exiterbara aminosyror - Google Patents

Reseptorantagonister av exiterbara aminosyror Download PDF

Info

Publication number
FI933810L
FI933810L FI933810A FI933810A FI933810L FI 933810 L FI933810 L FI 933810L FI 933810 A FI933810 A FI 933810A FI 933810 A FI933810 A FI 933810A FI 933810 L FI933810 L FI 933810L
Authority
FI
Finland
Prior art keywords
exiterbara
aminosyror
receptor antagonists
antagonists
receptor
Prior art date
Application number
FI933810A
Other languages
English (en)
Other versions
FI933810A0 (fi
FI933810A7 (fi
Inventor
Macklin Brian Arnold
Nancy Kay Augenstein
Carl Franklin Bertsch
Marvin Martin Hansen
Allen Robert Harkness
Bret Eugene Huff
William Henry Walker Lunn
Michael John Martinelli
Paul Leslie Ornstein
Darryle Darwin Schoepp
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI933810A0 publication Critical patent/FI933810A0/fi
Publication of FI933810L publication Critical patent/FI933810L/fi
Publication of FI933810A7 publication Critical patent/FI933810A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
FI933810A 1992-09-03 1993-08-31 Virittyvien aminohappojen reseptoriantagonisteja FI933810A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/939,780 US5284957A (en) 1992-09-03 1992-09-03 Excitatory amino acid receptor antagonists

Publications (3)

Publication Number Publication Date
FI933810A0 FI933810A0 (fi) 1993-08-31
FI933810L true FI933810L (fi) 1994-03-04
FI933810A7 FI933810A7 (fi) 1994-03-04

Family

ID=25473721

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933810A FI933810A7 (fi) 1992-09-03 1993-08-31 Virittyvien aminohappojen reseptoriantagonisteja

Country Status (26)

Country Link
US (7) US5284957A (fi)
EP (1) EP0590789B9 (fi)
JP (1) JP3601840B2 (fi)
KR (1) KR100274367B1 (fi)
CN (1) CN1043762C (fi)
AT (1) ATE234287T1 (fi)
AU (1) AU656482B2 (fi)
BR (1) BR9303495A (fi)
CA (2) CA2104909C (fi)
CZ (1) CZ285049B6 (fi)
DE (1) DE69332754T2 (fi)
DK (1) DK0590789T3 (fi)
ES (1) ES2194844T3 (fi)
FI (1) FI933810A7 (fi)
HU (2) HU224015B1 (fi)
IL (1) IL106809A (fi)
MX (1) MX9305294A (fi)
MY (1) MY131442A (fi)
NO (1) NO304072B1 (fi)
NZ (1) NZ248513A (fi)
PH (1) PH31250A (fi)
PL (1) PL173809B1 (fi)
PT (1) PT590789E (fi)
RU (1) RU2117661C1 (fi)
SG (1) SG45319A1 (fi)
ZA (1) ZA936231B (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087812B1 (es) * 1993-07-02 1997-03-16 Lilly Co Eli Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores.
US5580877A (en) * 1994-04-25 1996-12-03 Merck Sharp & Dohme Ltd. Pyrazolo-quinoline derivatives for treating cerebral ischemia
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N-取代的α-亚氨基异羟肟酸和羧酸
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
TR199802296T2 (xx) 1996-05-15 1999-02-22 Pfizer Inc. Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar
DE69716810T2 (de) * 1996-05-15 2003-02-27 Pfizer Inc., New York 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
JP2001521505A (ja) 1997-04-07 2001-11-06 イーライ・リリー・アンド・カンパニー 薬理学的物質
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JP2002505288A (ja) * 1998-03-02 2002-02-19 コセンシス,インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
TW513301B (en) * 1999-03-01 2002-12-11 Novartis Ag Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
CZ20014488A3 (cs) * 1999-07-06 2003-01-15 Eli Lilly And Company Selektivní antagonisté iGluR5 receptoru pro léčení migrény
ES2198323T3 (es) * 1999-07-06 2004-02-01 Eli Lilly And Company Profarmacos de diesteres de un acido decahidroisoquinolin-3-carboxilico.
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
WO2001046173A1 (en) * 1999-12-22 2001-06-28 Eli Lilly And Company SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS
ES2306690T3 (es) * 2001-01-05 2008-11-16 Eli Lilly And Company Antagonistas de receptores de aminoacidos excitatorios.
DZ3460A1 (fr) * 2001-01-05 2002-07-11 Lilly Co Eli Antagonistes du recepteur d'acide amine excitateur
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351951A2 (en) 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0106858D0 (en) * 2001-03-20 2001-05-09 Perkins Engines Co Ltd An accessory drive for driving an engine accessory
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7091249B2 (en) * 2001-12-26 2006-08-15 University Of Iowa Research Foundation Drugs for spinal anesthesia
WO2003082856A1 (en) * 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
AU2003226277B2 (en) * 2002-04-26 2009-03-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgesics
US20050176068A1 (en) * 2002-04-26 2005-08-11 Emmert-Buck Michael R. Direct cell target analysis
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
US20060220794A1 (en) * 2005-04-04 2006-10-05 Jeffrey Zhu Phase modulation for backscatter transponders
US20070293573A1 (en) * 2006-02-24 2007-12-20 Eric Gouaux Glu2 receptor modulators
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20090270508A1 (en) * 2007-02-23 2009-10-29 James Eric Gouaux GluR2 receptor modulators
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN101812031A (zh) * 2010-04-29 2010-08-25 南通市华峰化工有限责任公司 一种5-羟烷基四氮唑的高压生产方法
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
DK2935228T3 (en) 2012-12-20 2017-10-30 Inception 2 Inc TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
SG11201601066VA (en) 2013-09-06 2016-03-30 Inception 2 Inc Triazolone compounds and uses thereof
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
WO2022006537A1 (en) 2020-07-02 2022-01-06 Sea Pharmaceuticals Llc Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK704488D0 (da) * 1988-12-19 1988-12-19 Novo Industri As Nye n-substituerede azaheterocykliske carboxylsyrer
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4824959A (en) * 1988-02-18 1989-04-25 Bristol-Myers Company Intermediates for antihypercholesterolemic tetrazole compounds
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
MY131442A (en) 2007-08-30
US5670516A (en) 1997-09-23
HU9302453D0 (en) 1993-11-29
US5637712A (en) 1997-06-10
NO304072B1 (no) 1998-10-19
NO933100L (no) 1994-03-04
KR940007021A (ko) 1994-04-26
US5606062A (en) 1997-02-25
CN1091129A (zh) 1994-08-24
HK1013989A1 (en) 1999-09-17
DE69332754T2 (de) 2004-06-17
CN1043762C (zh) 1999-06-23
AU4600393A (en) 1994-03-10
RU2117661C1 (ru) 1998-08-20
US5648492A (en) 1997-07-15
ES2194844T3 (es) 2003-12-01
HUT65228A (en) 1994-05-02
AU656482B2 (en) 1995-02-02
US5675008A (en) 1997-10-07
EP0590789B9 (en) 2004-02-04
NO933100D0 (no) 1993-08-31
CA2104909A1 (en) 1994-03-04
US5284957A (en) 1994-02-08
HU224015B1 (hu) 2005-04-28
PH31250A (en) 1998-06-18
BR9303495A (pt) 1994-03-22
MX9305294A (es) 1994-06-30
EP0590789B1 (en) 2003-03-12
ATE234287T1 (de) 2003-03-15
KR100274367B1 (ko) 2000-12-15
ZA936231B (en) 1995-02-27
JPH06199802A (ja) 1994-07-19
JP3601840B2 (ja) 2004-12-15
DE69332754D1 (de) 2003-04-17
DK0590789T3 (da) 2004-03-22
SG45319A1 (en) 1998-01-16
FI933810A0 (fi) 1993-08-31
HU211992A9 (en) 1996-01-29
NZ248513A (en) 1996-02-27
FI933810A7 (fi) 1994-03-04
PT590789E (pt) 2003-07-31
CZ174593A3 (en) 1994-03-16
IL106809A (en) 1999-03-12
CZ285049B6 (cs) 1999-05-12
US5399696A (en) 1995-03-21
CA2484248A1 (en) 1994-03-04
CA2104909C (en) 2005-01-11
PL173809B1 (pl) 1998-05-29
EP0590789A1 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
FI933810L (fi) Reseptorantagonister av exiterbara aminosyror
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
DE69327720D1 (de) Endothelin rezeptor antagonisten
DE69232072D1 (de) Endothelin-rezeptor-antagonisten
FI914533A7 (fi) Fibrinogeenireseptoriantagonisteja
FI941178A7 (fi) 5-HT4-reseptoriantagonisteja
FI961804A7 (fi) Endoteliinireseptoriantagonistit
FI951249A7 (fi) Serotiinireseptoriaineita
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
MX9101311A (es) Antagonistas receptores de fibrinogeno
ID16742A (id) Antagonis reseptor endotelin
FI960516L (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
ATE213156T1 (de) Endothelin-rezeptor-antagonisten
FI943941L (fi) CCK-reseptoriantagonisteina käyttökelpoiset bentsodiatsepiinijohdannaiset
FI953916A7 (fi) Fibrinogeenireseptoriantagonisteja
NO179550C (no) Tachykinin reseptorantagonister
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
DE69616364D1 (de) Endothelinrezeptorantagonisten
FI943513L (fi) Kolekystokiniiniantagonisteina käyttökelpoisia 3-fenyyliureidoatsepin-2-oneja ja -bentsatsepin-2-oneja
FI930108A0 (fi) Imidazopyridin-paf-antagonister
LV10425A (lv) Fibrinogena receptoru antagonisti
FI922763A7 (fi) Difenyylisulfoksimiinimuskariinisia reseptoriantagonisteja
DK0660832T3 (da) Serotoninreceptor-midler